DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jsfnpr/global) has announced the addition of the "Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma" report to their offering.
2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. The authors find these regulations to be 'decisive' in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies. The implications of new price-reversions are going to have many facets and will change conventional business models. The authors expect many support services industries - CMOs, CROs and other allied services industries to benefit from these structural changes, while API importers will suffer. They also expect consolidation and M&A activities to spur in Japan.
Innovation Takes the Driver's Seat
While the new regulations will change the current business philosophy of doing business in patent expired space (>45% to total Japan market), the policy makers also discourage 'me too' innovations at the same time. The regulators however tend to support the 'first time in the world' level innovations by providing 'innovation premiums'. Japanese innovators will now become more serious and selective in their R&D approach.
Previous year the Japanese innovators have focused on acquiring assets in - autoimmune, orphan diseases and oncology fields (Annexure 5). The authors expect this trend to prevail in the coming years. They find some of the candidates to remain in the limelight in 2014 along with some new additions - Edoxaban (Daiichi Sankyo), Invokana (Mitsubishi Tanabe), Dolutegravir (Shionogi), BBI-608 (Dainippon Sumitomo), Vedolizumab (Takeda), Xtandi (Astellas), Nivolumab (Ono) to hand-pick a few of them. This report provides detailed analysis on these key candidates.
Key Topics Covered:
ASTELLAS: Successful Global Launch of Xtandi And Myrbetriq To Overcome Domestic worries!
STEDESA/Aptiom US approval and uptake
Other Pipeline candidates
- Daiichi Sankyo
- Dainnipon Sumitomo
- Kyowa Hakko Kirin
- Mitsubishi Tanabe
- Nippon Chemiphara
For more information visit http://www.researchandmarkets.com/research/jsfnpr/global